Table 1.
Baseline characteristics of patients
| Characteristic | Number of patients, N = 50 |
|---|---|
| Median age, years (range) | 49 (21–76) |
| Female/male | 21/29 |
| ECOG performance status | |
| 0 | 19 (38%) |
| 1 | 22 (44%) |
| 2 | 7 (14%) |
| 3 | 2 (4%) |
| Primary melanoma site, n (%) | |
| Cutaneous | 41 (82 %) |
| Uveal | 9 (18%) |
| M stage, n (%) | |
| M1a | 8 (16%) |
| M1b | 6 (12%) |
| M1c | 36 (72%) |
| M1c – brain | 9 (18 %)] |
| Number of previous lines of therapy, n (%) | |
| 1 | 34 (68%) |
| 2 | 10 (20%) |
| 3 | 6 (12%) |
| Median number of previous lines of therapy (range) | 1 (1–3) |
| LDH > ULN | 27 (54%) |
| Cancer Center, number of patients treated with ipilimumab | |
| Warsaw | 26 |
| Poznan | 11 |
| Lodz | 8 |
| Bialystok | 3 |
| Olsztyn | 2 |
ECOG – Eastern Cooperative Oncology Group; LDH – lactate dehydrogenase;ULN – upper limit of normal value